行情

PTGX

PTGX

Protagonist
NASDAQ

实时行情|Nasdaq Last Sale

10.68
-0.13
-1.16%
盘后: 10.68 0 0.00% 16:00 11/15 EST
开盘
10.84
昨收
10.80
最高
10.97
最低
10.57
成交量
23.77万
成交额
--
52周最高
16.67
52周最低
5.49
市值
2.90亿
市盈率(TTM)
-3.6250
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTGX 新闻

  • 欧央行总裁拉加德承诺在决策出现意见分歧时寻求对话
  • 新浪财经综合.39分钟前
  • 微软宣布开放神经网络交换格式已加入Linux基金会
  • 新浪财经综合.41分钟前
  • 冰火两重天的瑞幸
  • 钛媒体.1小时前
  • 脸书假新闻太多 维基百科创始人办了一个新社交网络
  • 新浪财经综合.1小时前

更多

所属板块

生物技术和医学研究
+1.35%
制药与医学研究
+1.27%

热门股票

名称
价格
涨跌幅

PTGX 简况

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
展开

Webull提供Protagonist Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。